01—Abstract
Summary
Summary of the 8-K filed July 24, 2025. Cited figures are marked; the original filing is the authoritative source.
Danaher Corporation (NYSE: DHR) announced in an 8-K filed July 24, 2025 that CFO Matthew McGrew will relinquish the CFO role effective February 28, 2026, remaining with the company as an Executive Vice President as he begins a gradual transition to retirement after more than 20 years at Danaher.
Matthew Gugino, currently Vice President of Corporate FP&A and Group CFO of the Life Sciences Innovations group, will succeed him as EVP and Chief Financial Officer on that date. Gugino, 43, has been with Danaher since 2013 and previously led Investor Relations from 2014 to 2022, giving him deep familiarity with both the financial reporting and investor communication functions. The filing discloses a meaningful compensation step-up for Gugino tied to the promotion.
His base salary rises to $700,000 immediately (July 21, 2025) and to $825,000a on February 28, 2026, with his target bonus moving to 90% for the remainder of 2025 and 115% from 2026. His equity grants increase to a $1.75 million target award in November 2025 and a $4.2 million target award for 2026, split between stock options and performance or time-vesting RSUs. McGrew's 2026 compensation is set at a $700,000 base salary, a 125% target bonus, and a $2.5 million equity target, reflecting his transition to a non-CFO executive role.
Gugino also signed a non-competition and proprietary interests agreement and receives added perquisites such as limited aircraft use and financial planning reimbursement. For investors, the announcement is primarily a planned, orderly succession rather than a signal of operational distress, since McGrew is staying on through the transition and the incoming CFO is an internal candidate with long institutional knowledge. The main points to monitor are continuity in capital allocation, M&A integration, and guidance credibility during the handover, as well as whether the more aggressive incentive structure for Gugino drives execution against Danaher's growth and margin targets.
02—Key points
Key Highlights
- CFO transition announced: Matthew McGrew steps down as CFO effective February 28, 2026, and remains as an Executive Vice President during a gradual retirement transition.
- Internal successor named: Matthew Gugino (43), currently VP-Corporate FP&A and Group CFO of Life Sciences Innovations, will become EVP and CFO; he has been at Danaher since 2013 and led Investor Relations from 2014 to 2022.
- Significant pay increase for successor: Gugino's base salary rises from an immediate $700,000 to $825,000 in February 2026, with target bonus increasing to 115% and 2026 equity target of $4.2 million.
- Equity award timing: Gugino receives a $1.75 million target equity award in November 2025, split equally between stock options and time-vesting RSUs.
- McGrew's post-CFO compensation: Effective February 28, 2026, McGrew's base salary is $700,000 with a 125% target bonus and a $2.5 million 2026 equity target.
- Retention and governance protections: Gugino signed a Protection of Proprietary Interests Agreement covering confidentiality, non-competition, non-solicitation, and IP assignment, and his severance under the Senior Leaders Severance Pay Plan equals his base salary at termination.
- Continuity messaging: CEO Rainer Blair credited McGrew with key roles in the Cytiva acquisition, the Envista and Veralto spin-offs, and the pandemic period, and characterized the handover as a seamless transition.
03—Questions
Frequently Asked Questions
Why is Danaher's CFO changing, and is this a sign of trouble?
The filing describes a planned transition. McGrew, who has been CFO since January 2019 and has been with Danaher more than 20 years, is starting a gradual move to retirement and will remain an Executive Vice President after the handover. The company characterizes it as consistent with past practice of retaining departing senior leaders. Nothing in the 8-K points to financial problems or disagreement.
Who is Matthew Gugino and how qualified is he to be CFO?
Gugino joined Danaher in 2013 as Director of Investor Relations and was Vice President of Investor Relations from 2014 to 2022. He has served as VP of Corporate FP&A since 2019 and as Group CFO of the Life Sciences Innovations group since 2021. Before Danaher, he was a Vice President of Equity Research at Barclays and Morgan Stanley and an Associate at KPMG. His background spans investor relations, FP&A, and M&A.
When does the CFO change take effect and what happens before then?
The change is effective February 28, 2026. Until then, McGrew remains CFO. Gugino's base salary increases to $700,000 and his target bonus rises to 90% effective July 21, 2025, and he receives a $1.75 million target equity award in November 2025 in connection with his promotion.
How much is the new CFO being paid, and does the pay package signal anything for investors?
From February 28, 2026, Gugino's base salary will be $825,000, with a 115% target bonus and a $4.2 million target annual equity award split between stock options and performance stock units. The inclusion of performance stock units in the 2026 award ties a meaningful portion of his compensation to performance goals, which aligns his incentives with shareholders. Severance is set at one year's base salary under the Senior Leaders Severance Pay Plan, equal to base salary at the time of termination.
Does the transition affect Danaher's near-term financial outlook?
The 8-K does not provide guidance or financial results, so it does not change reported expectations. Investors should watch whether the handover affects capital allocation, acquisition integration, and the consistency of guidance through early 2026, and whether McGrew's continued involvement as an EVP provides continuity during that period.
04—Continue